Review
[Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology]
[Article in
Spanish]
Affiliations
- PMID: 1896596
Item in Clipboard
Review
[Interleukin-2 and adoptive immunotherapy: their biological aspects and clinical application in oncology]
[Article in
Spanish]
Rev Clin Esp.
1991 May.
Abstract
Interleukin-2 (IL2), as a modifier of the biological response, has been intravenously used in patients with advanced cancer associated or not to LAK cells or tumor infiltrating lymphocytes. In different neoplasias positive results have been obtained, being effective in melanoma and renal cancer. There are still, at present, many questions to be answered and multiple research lines are currently open. The association with other cytokines and new chemotherapy protocols grant new therapeutic possibilities.
Similar articles
-
Adjuvant adoptive immunotherapy with IL2 and lymphocytes from tumor-bearing mice: in vitro tumor-stimulated lymphocytes are more effective than LAK cells.Nat Immun Cell Growth Regul. 1991;10(6):308-19. Nat Immun Cell Growth Regul. 1991. PMID: 1787836
-
Therapy with interleukin-2 and tumor-derived activated lymphocytes.Immunol Ser. 1994;61:251-71. Immunol Ser. 1994. PMID: 8011748 Review. No abstract available.
-
[Immunotherapy of malignant melanoma].Pathol Biol (Paris). 1990 Oct;38(8):881-2. Pathol Biol (Paris). 1990. PMID: 2274397 French. No abstract available.
-
Adoptive immunotherapy of advanced solid tumors: an eight year clinical experience.Anticancer Res. 1999 Nov-Dec;19(6C):5645-9. Anticancer Res. 1999. PMID: 10697634 Review.
-
Interleukin 2 in cancer therapy.Ann Ist Super Sanita. 1990;26(3-4):283-334. Ann Ist Super Sanita. 1990. PMID: 2091501 Review.